## ABVX: Abivax SA - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.1% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($103.03)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Abivax SA Sponsored ADR $ABVX Shares Acquired by Kennedy Capital Management LLC**
- Source: MarketBeat | 20251208T111009 | Bullish | Relevance: 97%
-  Kennedy Capital Management LLC increased its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 7.1% during the second quarter, now owning 241,188 shares valued at $1.85 million. Several other institutional investors also increased their holdings, bringing total institutional ownership to 47.91%. Analysts currently rate Abivax with a "Moderate Buy" and an average target price of $123.00, while the company's lead drug candidate, obefazimod, is in Phase 3 trials for ulcerative colitis.

**2. Quadrature Capital Ltd Acquires Shares of 19,367 Abivax SA Sponsored ADR $ABVX**
- Source: MarketBeat | 20251206T050051 | Somewhat-Bullish | Relevance: 97%
- Quadrature Capital Ltd has acquired a new position of 19,367 shares of Abivax (NASDAQ:ABVX) in Q2, valued at approximately $148,000, bringing institutional ownership of the stock to roughly 47.91%. Abivax, a clinical-stage biotech company developing obefazimod for ulcerative colitis, has a market cap of $8.61 billion, and analysts have a "Moderate Buy" consensus rating with a target price of $123.00. The company reported a -$0.86 EPS last quarter, slightly surpassing estimates.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Truist Securiti | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Truist Securiti | init | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- TCG Crossover Manage: 9.1% (+17.4%)
- UBS Group AG: 5.7% (+2561.0%)
- Darwin Global Manage: 4.1% (+100.0%)
- Point72 Asset Manage: 3.8% (+1642.4%)
- Cormorant Asset Mana: 2.5% (-8.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.0% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Revenue growth strong at 721% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.0B |
| Beta | -0.11 |
| 52W Range | $4.77 - $130.25 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from -0.1% to -2.1% (-2.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.1pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.4%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 2.44x) but short-term weakness (below SMA20). MACD histogram bearish (-1.62), momentum weakening. RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.14% (CS: 39) | Weak |
| RSI_14 | 54.9 | Neutral |
| MACD Histogram | -1.62 | Bearish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 1.129x | Above |
| vs SMA200 | 2.438x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $115.05
- **Stop Loss:** $103.03 (10.4% risk)
- **Target:** $127.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 41
- **Position Value:** $4,717.05
- **Portfolio %:** 4.72%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-03-23 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*